Quantitative analysis for Nektar Therapeutics (NKTR) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (74.0) (grade A). 25 signals analyzed (21 differentiated alt-data).
NKTR stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $85.00 | $81.30 | $83.20 |
| 2026-05-11 | $80.95 | $76.61 | $78.72 |
| 2026-05-21 | $69.85 | $68.07 | $68.58 |
| 2026-06-03 | $60.08 | $58.16 | $59.23 |
| 2026-06-15 | $61.51 | $59.84 | $61.15 |
| 2026-06-26 | $64.34 | $61.29 | $63.65 |
| 2026-07-09 | $73.54 | $71.25 | $72.92 |
| 2026-07-21 | $68.74 | $64.24 | $68.67 |
| 2026-07-31 | $71.43 | $69.50 | $70.67 |
| 2026-08-12 | $76.74 | $75.42 | $76.03 |
| 2026-08-24 | $74.36 | $70.93 | $73.69 |
| 2026-09-03 | $76.63 | $72.99 | $76.37 |
How Nektar Therapeutics stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $1.4B | — |
| DMRA | Galecto, Inc. | $1.5B | — |
| MLTX | MoonLake Immunotherapeutics | $1.3B | — |
| IMCR | Immunocore Holdings plc | $1.5B | — |
View all Health Care stocks by valuation and signals →
Nektar Therapeutics (NKTR) scores Strong Buy (74.0), with no measured dimension below 69. Its highest are competitive moat at 87, technicals at 86, analyst consensus at 69, across 3 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 87 |
| technicals | 86 |
| analyst consensus | 69 |
StoQuant analyzes 25 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Nektar Therapeutics (NKTR): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/NKTR"><img src="https://stoquant.com/badge/NKTR.svg" alt="Nektar Therapeutics (NKTR) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.